Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AIR T INCAIRT · Entity 6862 | CFO | November 30, 2018 | December 04, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AIR T INC
Report date November 30, 2018 · Filed December 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $31.00 · Expires 2028-11-30 | Direct | 25,000 |
Reported balance
After 2018-11-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-11-30 · Grant · Acquired 25,000 · Balance 25,000 F1: Up to 20% of the warrant shares may be purchased at any time after June 30, 2019. Up to 40% of the warrant shares (less any shares previously purchased) may be purchased at any time after June 30, 2020. Up to 60% of the warrant shares (less any shares previously purchased) may be purchased at any time after June 30, 2021. Up to 80% of the warrant shares (less any shares previously purchased) may be purchased at any time after June 30, 2022. Up to 100% of the warrant shares (less any shares previously purchased) may be purchased at any time after June 30, 2023. Vested warrants remain vested and exercisable in accordance with the terms of agreement following a termination of employment with the Company for any reason. Upon termination of employment with the Company for any reason, unvested warrants will vest pro-rata for the days of employment in that year. |
Filing footnotes · ownership attribution and instrument terms
F1: Up to 20% of the warrant shares may be purchased at any time after June 30, 2019. Up to 40% of the warrant shares (less any shares previously purchased) may be purchased at any time after June 30, 2020. Up to 60% of the warrant shares (less any shares previously purchased) may be purchased at any time after June 30, 2021. Up to 80% of the warrant shares (less any shares previously purchased) may be purchased at any time after June 30, 2022. Up to 100% of the warrant shares (less any shares previously purchased) may be purchased at any time after June 30, 2023. Vested warrants remain vested and exercisable in accordance with the terms of agreement following a termination of employment with the Company for any reason. Upon termination of employment with the Company for any reason, unvested warrants will vest pro-rata for the days of employment in that year.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
COGENTIX MEDICAL INC /DE/
Report date April 20, 2018 · Filed April 23, 2018
Section 16 reporting ended · disclosed 2018-04-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-04-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-04-20 · Other · Disposed 81,405 · Balance 100,458 F1: On April 20, 2018, these shares were purchased in a tender offer for all of the issued and outstanding shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. (the Company") by Camden Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of LM US Parent, Inc. and Laborie Medical Technologies Canada ULC, pursuant to the Agreement and Plan of Merger dated as of March 11, 2018 (the "Merger Agreement"). Row 2 · 2018-04-23 · Disposition to issuer · Disposed 100,458 · Balance 0 F2: Pursuant to the Merger Agreement, upon the effectiveness of the merger of Merger Sub with and into the Company (the "Merger"), these shares of restricted stock were cancelled and converted into the right to receive a cash payment of $3.85 per share, net to the reporting person in cash, without interest and less any applicable withholding taxes (the "Merger Consideration"). |
| Stock Option (Right toBuy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.88 · Expires 2023-06-13 | Direct | 0 |
Reported balance
After 2018-04-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-04-23 · Disposition to issuer · Disposed 150,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon effectiveness of the Merger, these options were cancelled and converted into the right to receive a cash payment equal to the product of (A) the total number of shares subject to such option and (B) the excess, if any, of the Merger Consideration over the exercise price per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2023-06-29 | Direct | 0 |
Reported balance
After 2018-04-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-04-23 · Disposition to issuer · Disposed 33,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon effectiveness of the Merger, these options were cancelled and converted into the right to receive a cash payment equal to the product of (A) the total number of shares subject to such option and (B) the excess, if any, of the Merger Consideration over the exercise price per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2027-05-19 | Direct | 0 |
Reported balance
After 2018-04-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-04-23 · Disposition to issuer · Disposed 226,027 · Balance 0 F3: Pursuant to the Merger Agreement, upon effectiveness of the Merger, these options were cancelled and converted into the right to receive a cash payment equal to the product of (A) the total number of shares subject to such option and (B) the excess, if any, of the Merger Consideration over the exercise price per share. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 20, 2018, these shares were purchased in a tender offer for all of the issued and outstanding shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. (the Company") by Camden Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of LM US Parent, Inc. and Laborie Medical Technologies Canada ULC, pursuant to the Agreement and Plan of Merger dated as of March 11, 2018 (the "Merger Agreement").
F2: Pursuant to the Merger Agreement, upon the effectiveness of the merger of Merger Sub with and into the Company (the "Merger"), these shares of restricted stock were cancelled and converted into the right to receive a cash payment of $3.85 per share, net to the reporting person in cash, without interest and less any applicable withholding taxes (the "Merger Consideration").
F3: Pursuant to the Merger Agreement, upon effectiveness of the Merger, these options were cancelled and converted into the right to receive a cash payment equal to the product of (A) the total number of shares subject to such option and (B) the excess, if any, of the Merger Consideration over the exercise price per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2018 Filed Dec 4, 2018 16:46 UTC | AIR T INC AIRT · Entity 6862 | GrantStock Warrants · Derivative | 25,000 | $31.00 Strike: $31.00 | $775,000.00 |
DisclosureSEC source: 0000353184-18-000048 · primary_doc.xml · derivative · entry 1 Reynolds Brett · CIK 0001323150 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Stock Warrants · 25,000 shares Expires 2028-11-30 F1 · derivative.exercise_date: Up to 20% of the warrant shares may be purchased at any time after June 30, 2019. Up to 40% of the warrant shares (less any shares previously purchased) may be purchased at any time after June 30, 2020. Up to 60% of the warrant shares (less any shares previously purchased) may be purchased at any time after June 30, 2021. Up to 80% of the warrant shares (less any shares previously purchased) may be purchased at any time after June 30, 2022. Up to 100% of the warrant shares (less any shares previously purchased) may be purchased at any time after June 30, 2023. Vested warrants remain vested and exercisable in accordance with the terms of agreement following a termination of employment with the Company for any reason. Upon termination of employment with the Company for any reason, unvested warrants will vest pro-rata for the days of employment in that year. Read SEC document |
| April 23, 2018 Filed Apr 23, 2018 17:08 UTC | COGENTIX MEDICAL INC /DE/ CGNT · Entity 167360 | Disposition to issuerStock Option (Right to Buy) · Derivative | 226,027 | $2.20 Strike: $1.65 | $497,259.40 |
DisclosureSEC source: 0001437749-18-007489 · rdgdoc.xml · derivative · entry 5 Reynolds Brett · CIK 0001323150 · SVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 226,027 shares Expires 2027-05-19 F3 · shares: Pursuant to the Merger Agreement, upon effectiveness of the Merger, these options were cancelled and converted into the right to receive a cash payment equal to the product of (A) the total number of shares subject to such option and (B) the excess, if any, of the Merger Consideration over the exercise price per share. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, upon effectiveness of the Merger, these options were cancelled and converted into the right to receive a cash payment equal to the product of (A) the total number of shares subject to such option and (B) the excess, if any, of the Merger Consideration over the exercise price per share. Read SEC document |
| April 23, 2018 Filed Apr 23, 2018 17:08 UTC | COGENTIX MEDICAL INC /DE/ CGNT · Entity 167360 | Disposition to issuerStock Option (Right to Buy) · Derivative | 33,000 | $2.82 Strike: $1.03 | $93,060.00 |
DisclosureSEC source: 0001437749-18-007489 · rdgdoc.xml · derivative · entry 4 Reynolds Brett · CIK 0001323150 · SVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Commn Stock · 33,000 shares Expires 2023-06-29 F3 · shares: Pursuant to the Merger Agreement, upon effectiveness of the Merger, these options were cancelled and converted into the right to receive a cash payment equal to the product of (A) the total number of shares subject to such option and (B) the excess, if any, of the Merger Consideration over the exercise price per share. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, upon effectiveness of the Merger, these options were cancelled and converted into the right to receive a cash payment equal to the product of (A) the total number of shares subject to such option and (B) the excess, if any, of the Merger Consideration over the exercise price per share. Read SEC document |
| April 23, 2018 Filed Apr 23, 2018 17:08 UTC | COGENTIX MEDICAL INC /DE/ CGNT · Entity 167360 | Disposition to issuerStock Option (Right toBuy) · Derivative | 150,000 | $2.97 Strike: $0.88 | $445,485.00 |
DisclosureSEC source: 0001437749-18-007489 · rdgdoc.xml · derivative · entry 3 Reynolds Brett · CIK 0001323150 · SVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2023-06-13 F3 · shares: Pursuant to the Merger Agreement, upon effectiveness of the Merger, these options were cancelled and converted into the right to receive a cash payment equal to the product of (A) the total number of shares subject to such option and (B) the excess, if any, of the Merger Consideration over the exercise price per share. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, upon effectiveness of the Merger, these options were cancelled and converted into the right to receive a cash payment equal to the product of (A) the total number of shares subject to such option and (B) the excess, if any, of the Merger Consideration over the exercise price per share. Read SEC document |
| April 23, 2018 Filed Apr 23, 2018 17:08 UTC | COGENTIX MEDICAL INC /DE/ CGNT · Entity 167360 | Disposition to issuerCommon Stock | 100,458 | $3.85 | $386,763.30 |
DisclosureSEC source: 0001437749-18-007489 · rdgdoc.xml · nonDerivative · entry 2 Reynolds Brett · CIK 0001323150 · SVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Pursuant to the Merger Agreement, upon the effectiveness of the merger of Merger Sub with and into the Company (the "Merger"), these shares of restricted stock were cancelled and converted into the right to receive a cash payment of $3.85 per share, net to the reporting person in cash, without interest and less any applicable withholding taxes (the "Merger Consideration"). Read SEC document |
| April 20, 2018 Filed Apr 23, 2018 17:08 UTC | COGENTIX MEDICAL INC /DE/ CGNT · Entity 167360 | OtherCommon Stock | 81,405 | $3.85 | $313,409.25 |
DisclosureSEC source: 0001437749-18-007489 · rdgdoc.xml · nonDerivative · entry 1 Reynolds Brett · CIK 0001323150 · SVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,458 F1 · shares: On April 20, 2018, these shares were purchased in a tender offer for all of the issued and outstanding shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. (the Company") by Camden Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of LM US Parent, Inc. and Laborie Medical Technologies Canada ULC, pursuant to the Agreement and Plan of Merger dated as of March 11, 2018 (the "Merger Agreement"). Read SEC document |
| May 19, 2017 Filed May 23, 2017 16:47 UTC | COGENTIX MEDICAL INC /DE/ CGNT · Entity 167360 | GrantStock Option (Right to Buy) · Derivative | 226,027 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001437749-17-009917 · rdgdoc.xml · derivative · entry 2 Reynolds Brett · CIK 0001323150 · SVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,027 Underlying: Common Stock · 226,027 shares Expires 2028-05-19 F2 · derivative.exercise_date: This option vests in cumulative annual installments of one-third each, beginning the date shown. Read SEC document |
| May 19, 2017 Filed May 23, 2017 16:47 UTC | COGENTIX MEDICAL INC /DE/ CGNT · Entity 167360 | GrantCommon Stock | 31,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-009917 · rdgdoc.xml · nonDerivative · entry 1 Reynolds Brett · CIK 0001323150 · SVP, CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,863 F1 · shares: These shares vest in one-third increments pursuant to a restricted stock award beginning on the first anniversary of the grant date. F3 · balance_after: Total holdings include restricted stock awards. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.